Chaotic Reaction In After-Hours for Alnylam Pharmaceuticals (ALNY); Patent Victory for Shire (SHPG)


Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY) shares slumped more than 40% to touch a new 52-week low in after-hours trading Wednesday as the company said that it is discontinuing further development of its drug revusiran for the treatment of hereditary amyloidosis with cardiomyopathy

ALNY stock finished the regular session at $70.30, up $1.73 (or +2.52%) with a total volume of 1.90M shares traded, representing a large increase in activity versus its average volume (3m) of 650,401

Alnylam Pharmaceuticals, which discovers, develops, and commercializes novel therapeutics based on RNA interference, has 85.72M Shares Outstanding. At close on Wednesday, the biopharmaceutical company had a Market Capitalization of $6.03B and ALNY stock one-year range was between $49.96 and $110.75 per share



Shire plc (Nasdaq:SHPG) stock closed in negative territory by 0.11% (or -$0.22) at $194.37 on Wednesday’s trading session, and 1.13M of its shares changed hands during the day

The global biotechnology company said after the closing bell that the USPTO’s Patent Trial and Appeal Board found that the patent protecting its ulcerative colitis drug Lialda was valid

Shire, which researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products, has 300.07M Shares Outstanding, Market Capitalization (intraday) of $58.65B and SHPG stock 52-week range is from $147.60 to $231.32 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at